Startups
Bluebird bio reported first-quarter earnings, the approval of Abecma, the first CAR-T therapy for relapsed or refractory multiple myeloma, and its spinout, 2seventy bio, and its leadership.
There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look.
April showers bring May dollars. Here’s whose cash gardens are really blooming this week in the life sciences world.
Neuroelectrics, based in Barcelona, Spain with offices in Cambridge, Massachusetts, announced it had raised $17.5 million in a Series A financing round. It was led by Morningside Ventures.
Grabbing a fast-tracked novel enzyme replacement therapy for a rare pediatric disease, new biopharma Aceragen launched with $35 million in hand for product financing.
The California biotech aspires to be a catalyst for the acceleration of gene therapy across a range of therapeutic areas, beginning with three serious neurodegenerative disease targets.
Two months after Centessa Pharmaceuticals launched following the merger of 10 private biotech companies, the company is already eying a $100 million splash on the Nasdaq stock exchange.
Six months after bagging $115 million in a Series B financing round, Talaris Therapeutics is aiming to raise another $100 million through in initial public offering. It’s one of three companies joining in the flurry of IPOs this week.
Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week.
Several companies launched with Series A financing rounds today. Read on for details.
PRESS RELEASES